載入...
2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
BACKGROUND: The respiratory syncytial virus (RSV) fusion glycoprotein (F) is a molecule that fuses the viral and host cell membranes during virus entry as it rearranges from a meta-stable prefusion to a stable postfusion conformation. Using structure-guided design, Pfizer engineered a prefusion RSV...
Na minha lista:
發表在: | Open Forum Infect Dis |
---|---|
Main Authors: | , , , , , , , , , , |
格式: | Artigo |
語言: | Inglês |
出版: |
Oxford University Press
2019
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6809502/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.2432 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|